Which agent is preferred for the treatment of uncontrolled variceal bleeding due to its favorable side-effect profile?

The preferred agent for the treatment of uncontrolled variceal bleeding, especially noted for its favorable side-effect profile, is somatostatin. Somatostatin works by reducing portal hypertension through a decrease in portal blood flow, which can help to manage the bleeding from varices effectively.

This agent is often favored in clinical settings because it typically has fewer adverse effects compared to other options like vasopressin, which can cause significant cardiovascular side effects such as ischemia, or terlipressin, which, while effective, can also have concerning side effects like increased blood pressure. Octreotide, while effective as well, may not always present the same optimal side-effect profile and is often less favorable in the context of variceal hemorrhage compared to somatostatin.

In essence, somatostatin's utility and safety make it a preferred choice in the management of variceal bleeding, effectively addressing the condition while minimizing potential complications.